<![CDATA[Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC]]>
Phase 3positiveBelzutifanLenvatinibCabozantinibPositive
AI Analysis
Summary
Phase 3 LITESPARK-011 trial results demonstrate that belzutifan/lenvatinib combination significantly improved progression-free survival and overall response rate compared to cabozantinib in previously treated advanced clear cell renal cell carcinoma.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Belzutifan/lenvatinib combination significantly improved progression-free survival (PFS) and overall response rate (ORR) versus cabozantinib in previously treated advanced clear cell RCC (ccRCC)
Importance:8/10
Sentiment:
0.80
Phase 3OncologyRenal cell carcinomaCombination therapyClinical trial
Read the original article
Published by Cancer Network on August 20, 2026 3:00 PM